1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Lundbeck
  6. Summary
    LUN   DK0061804697

LUNDBECK

(LUN)
  Report
Delayed Nasdaq Copenhagen  -  10:59 2022-07-01 am EDT
35.60 DKK   +4.52%
06/27TRANSCRIPT : H. Lundbeck A/S - Shareholder/Analyst Call
CI
06/27CORRECTION ( : Markets-Morning UPDATE1:)
AQ
06/27H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
06/27/2022 06/28/2022 06/29/2022 06/30/2022 07/01/2022 Date
37.7(c) 35.8(c) 34.6(c) 34.06(c) 35.6(c) Last
1 592 992 800 082 181 071 296 040 610 293 Volume
+11.87% -5.04% -3.35% -1.56% +4.52% Change
More quotes
Estimated financial data (e)
Sales 2022 17 258 M 2 413 M 2 413 M
Net income 2022 1 521 M 213 M 213 M
Net Debt 2022 1 973 M 276 M 276 M
P/E ratio 2022 -
Yield 2022 -
Sales 2023 18 798 M 2 629 M 2 629 M
Net income 2023 2 558 M 358 M 358 M
Net cash position 2023 1 207 M 169 M 169 M
P/E ratio 2023 -
Yield 2023 -
Capitalization 35 750 M 4 999 M 4 999 M
EV / Sales 2022 2,19x
EV / Sales 2023 1,84x
Nbr of Employees 5 353
Free-Float 30,7%
More Financials
Company
H. Lundbeck A/S specializes in the development, production and marketing of medicines for the treatment of psychiatric and neurological disorders (depression, schizophrenia, Lennox-Gastaut syndrome, Parkinson's disease, Huntington's disease, epilepsy, sleep disorders, etc.). 
Sector
Pharmaceuticals
Calendar
08/17Earnings Release
More about the company
Ratings of Lundbeck
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about LUNDBECK
06/27TRANSCRIPT : H. Lundbeck A/S - Shareholder/Analyst Call
CI
06/27CORRECTION ( : Markets-Morning UPDATE1:)
AQ
06/27H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agi..
CI
06/26Lundbeck and Otsuka Pharmaceutical announce positive results showing reduced agitation ..
AQ
06/20Otsuka's European Unit Gets Clearance to Market Schizophrenia Drug
MT
06/17European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectab..
CI
06/16Results from the DELIVER study with Vyepti« has been published in a top-ranking medical..
AQ
06/16H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti
CI
06/14H. LUNDBECK A/S(CPSE : HLUN A) added to OMX Nordic All-Share Index
CI
06/10H. LUNDBECK A/S(CPSE : HLUN B) added to FTSE All-World Index
CI
06/10H. LUNDBECK A/S(CPSE : HLUN B) added to OMX Nordic All-Share Index
CI
06/10H. LUNDBECK A/S(CPSE : HLUN B) added to FTSE All-World Index
CI
06/09H. LUNDBECK A/S(CPSE : LUN) dropped from OMX Nordic All-Share Index
CI
06/08Lundbeck Extraordinary General Meeting on June 8, 2022 at the company's registered offi..
AQ
06/08TRANSCRIPT : H. Lundbeck A/S - Shareholder/Analyst Call
CI
More news
News in other languages on LUNDBECK
06/27POINT SUR LES FORTES VARIATIONS DU J : Prosus s'éloigne de Tencent
06/27H. Lundbeck A/S et Otsuka Pharmaceutical annoncent des résultats positifs montrant une ..
06/17L'Agence européenne des médicaments commence l'examen de l'injectable à action prolongé..
06/16H. Lundbeck A/S annonce les résultats de l'étude Deliver avec Vyepti
06/15L'agenda di oggi
More news
Analyst Recommendations on LUNDBECK
More recommendations
Chart LUNDBECK
Duration : Period :
Lundbeck Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LUNDBECK
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 35,60 DKK
Average target price 167,00 DKK
Spread / Average Target 369%
Managers and Directors
Deborah L. Dunsire President & Chief Executive Officer
Anders G÷tzsche Chief Financial Officer & Executive Vice President
Lars S°ren Rasmussen Chairman
Lars Bang Executive VP-Supply Operations & Engineering
Johan Luthman EVP & Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
LUNDBECK-78.92%4 999
JOHNSON & JOHNSON3.76%472 389
PFIZER, INC.-11.21%293 506
ELI LILLY AND COMPANY17.38%292 291
ROCHE HOLDING AG-15.48%272 104
ABBVIE INC.13.59%271 782